US FDA Increases Surprise Inspections At Indian Pharmaceutical Plants

The US Food and Drug Administration (FDA) has intensified unannounced inspections at pharmaceutical manufacturing facilities in India, signalling tighter scrutiny of drug quality and safety standards. The move is significant as India supplies nearly 40% of the generic medicines used in the United States.

Earlier, a smaller proportion of FDA inspections in India took place without prior notice. During the 12 months preceding the latest reporting period, 47% of audits were unannounced. However, this figure rose sharply to 87% in the financial year ended March 31, 2026, indicating a shift towards more stringent and surprise-based monitoring.

The changing inspection pattern means Indian drugmakers now face more frequent unannounced checks, which places greater emphasis on consistent compliance and manufacturing quality.

a

Magazine made for you.